BioSpace News Archive

Data published evaluates fibrodysplasia ossificans progressiva (FOP) natural disease progression

Nanobiotix has been able to maintain business continuity and drive key strategic priorities throughout the first half of 2020.

Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, Cancer Research UK and Cambridge University Hospitals NHS Foundation Trust, announce a collaboration to identify and develop microbiome co-therapeutics and biomarkers for cancer patients receiving immune checkpoint inhibitor therapy.

The Canadian Medical Association released a national poll showing that Canadians are embracing virtual care options and would like to see them not only continued after the COVID-19 crisis subsides but improved and expanded in the future.

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, announced that it has selected development candidate, IDE397, for its Methionine adenosyltransferase 2a Synthetic Lethality program.

The CoVisa™ IgG ELISA-based test enables widely available ELISA systems to add capacity to the high-quality closed testing platforms currently in place

PBCAR269A Targets BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma and is the Company’s Third Investigational Allogeneic CAR T Candidate Advanced to the Clinic

DalCor Pharmaceuticals announced the appointment of Diane E. Sullivan as Chief Commercial Officer effective June 1, 2020.

Applied Therapeutics, Inc. announced that three abstracts have been selected, including one oral presentation, at the upcoming American Diabetes Association’s 80th Scientific Sessions: A Virtual Experience taking place June 12-16, 2020.

Research to address health disparities, inform public health response in communities of color